PHARMACEUTICAL PRODUCTS CONTAINING HORMONES AND A 25-HYDROXY VITAMIN D COMPOUND
First Claim
Patent Images
1. A composition comprising 25-hydroxy Vitamin D compound and a progestin, wherein the dosage of said Vitamin D compound is in the range of 41-560 mcg.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to pharmaceutical products containing progestins in combination with the 25 hydroxy Vitamin D compounds. The 25 hydroxy Vitamin D compounds are preferably administered with the progestins. In OC and HRT regimens, the 25 hydroxy Vitamin D compounds can be administered daily, or on a non-daily basis, and if so, preferably when the progestin dosages are the highest in the cycle.
49 Citations
46 Claims
- 1. A composition comprising 25-hydroxy Vitamin D compound and a progestin, wherein the dosage of said Vitamin D compound is in the range of 41-560 mcg.
- 21. A pharmaceutical combination comprising 21 daily sequential dosages, said product including 21 sequential daily hormone dosages, with at least one hormone dosage comprising a progestin product, and optionally estrogen, and wherein the remaining daily hormone dosages include estrogen, and optionally a progestin product, and with at least one of said dosages further comprising a 25-hydroxy Vitamin D compound in the range of 35-560 mcg, and at least another one of said hormone dosages has Vitamin D in the range of 0-10 mcg.
- 43. A pharmaceutical combination comprising 28 daily sequential dosages, said product including 21 sequential daily hormone dosages, with at least one hormone dosage comprising a progestin product, and optionally estrogen, and wherein the remaining daily hormone dosages include estrogen, and optionally a progestin product, and with at least one of said dosages further comprising a 25-hydroxy Vitamin D compound in the range of 35-560 mcg, and at least another one of said hormone dosages has Vitamin D in the range of 0-10 mcg, and said combination further comprising 7 additional daily sequential dosages, wherein said additional dosages may include progestin and/or estrogen, or alternatively have no estrogen and no progestins, and wherein at least one of said additional dosages includes a 25-hydroxy Vitamin D compound in the range of 35-560 mcg.
Specification